Medtide

Medtide EBITDA per Employee

The EBITDA per Employee of Medtide (3880.HK) as of Oct 15, 2026 is 430,637.93 CNY. In the previous year, EBITDA per Employee was 312,226.05 CNY — a change of 37.93% (higher).

EBITDA per Employee

430,637.93CNY

YoY

37.93%

Last updated:

EBITDA per Employee of Medtide is 2025 430,637.93 CNY. EBITDA per Employee of Medtide was 2024 312,226.05 CNY. It decreases by 37.93% higher compared to the previous year.

The Medtide EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2021
172,519.16 CNY
Jan 1, 2022
260,348.66 CNY
Jan 1, 2023
206,078.54 CNY
Jan 1, 2024
312,226.05 CNY
Jan 1, 2025
430,637.93 CNY
The Medtide EBITDA per Employee history
YEAREBITDA per EmployeeYoY
430,637.93CNY+37.93%
312,226.05CNY+51.51%
206,078.54CNY-20.85%
260,348.66CNY+50.91%
172,519.16CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medtide Stock analysis

What does Medtide do? Medtide Inc, listed on the Hong Kong Stock Exchange under ticker 3880.HK, is a life sciences company headquartered in Hangzhou, China. The company, which has 522 full-time employees, specializes in peptide-focused contract research, development, and manufacturing services. Medtide provides contract research organization (CRO) services, including peptide new chemical entity (NCE) discovery and synthesis, as well as contract development and manufacturing organization (CDMO) services covering peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The company's primary focus is on delivering active pharmaceutical ingredients (APIs) rather than finished drug products. Medtide also offers peptide drug development, production, and CMC filing support services to its clients. The firm serves both domestic and international markets, operating across multiple regions. Medtide's initial public offering (IPO) is scheduled for June 30, 2025, as indicated by its IPO date. The company's website is http://medtideinc.com, where further information about its services and operations can be found. Medtide Inc. operates within the Health Care sector, specifically in the Life Sciences Tools & Services industry, reflecting its specialized role in the pharmaceutical and biotechnology fields. The company's business model centers on providing comprehensive solutions for peptide-based drug development and manufacturing, targeting clients seeking expertise in this niche area of pharmaceutical services. Medtide is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medtide stock

EBITDA per Employee of Medtide is 430,637.93 CNY in 2025.

EBITDA per Employee of Medtide changed from 312,226.05 CNY to 430,637.93 CNY, representing a 37.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Medtide since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Medtide historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Medtide

All Key Metrics — Medtide